Abstract: Enteral formulations containing including therapeutically effective amount carbon monoxide, and methods of use thereof, for treatment of ocular diseases and disorders are provided. The formulations can be administered in a subject in need thereof in an effective amount to reduce or prevent an ocular disease in the subject, and thus reduce one or more symptoms of disease, disorder, or illness associated with the disease. In some embodiments, the formulation is administered orally.

Abstract: A method, apparatus (800), and system (900) for a water activated neck seal tension relief device are described. The system (900) includes a liner (902), such as that of a protective suit, and an actuator apparatus (800) disposed within the liner (902). The apparatus (800) includes a resilient member (200) and a coupling (802), the coupling (802) including a body (600) configured to receive a first (810) and a second (808) portion of the resilient member (200). The liner (902), body (600) and resilient member (200) define a substantially circular opening. A restraint (804) is mounted on the body (600) and configured to restrain the second portion (808) of the resilient member (200) in relation to the body (600) to maintain the resilient member (200) in a first position at which the opening has a first diameter (702). The restraint (804) is configured to release the second portion (808) of the resilient member (200) when the restraint (804) is exposed to water.

Abstract: This invention relates to a stabilized aqueous glutaraldehyde solution including 0.005% to 45% m/v, suitably 10% to 45% m/v solution of glutaraldehyde, an alcohol ethoxylate non-ionic surfactant, a buffer and a sufficient amount of a pH modifier to bring the pH of the solution to 6.0 to 8.5. The glutaraldehyde and the alcohol ethoxylate non-ionic surfactant are chemically bound together, suitably by complexing. These stable solutions can be stored for a period of at least six months without the glutaraldehyde polymerizing or the pH dropping below 5.0.

Abstract: A method of manufacturing a stable aldehyde-surfactant complex solution wherein at least one aldehyde is added to a surfactant in a first aliquot of water, at a temperature of between 40° C. to 50° C., the aldehyde is allowed to interact with the surfactant or detergent, in a complexing reaction, for at least 15 minutes whilst maintaining the temperature between 40° C. to 50° C. to produce an aldehyde-surfactant complex solution, and a second aliquot of water is added after at least 15 minutes to cool the aldehyde-surfactant complex solution to below 40° C. to stop the complexing reaction.

Abstract: A method of manufacturing a stable aldehyde-surfactant complex solution wherein at least one aldehyde is added to a surfactant in a first aliquot of water, at a temperature of between 40° C. to 50° C., the aldehyde is allowed to interact with the surfactant or detergent, in a complexing reaction, for at least 15 minutes whilst maintaining the temperature between 40° C. to 50° C. to produce an aldehyde-surfactant complex solution, and a second aliquot of water is added after at least 15 minutes to cool the aldehyde-surfactant complex solution to below 40° C. to stop the complexing reaction.

Abstract: A stable glutaraldehyde polymer complex solution which includes: (a) glutaraldehyde (OCH(CH2)3CHO) in a 0.005% to 45% m/v concentration; (b) a non-ionic surfactant; (c) a buffer; (d) a sufficient amount of a pH modifier to bring the pH of the solution to within a 6.0 to 9.0 range; and (e) a polymer.

Abstract: This invention relates to a stabilised aqueous glutaraldehyde solution including 0.005% to 45% m/v, suitably 10% to 45% m/v solution of glutaraldehyde, an alcohol ethoxylate non-ionic surfactant, a buffer and a sufficient amount of a pH modifier to bring the pH of the solution to 6.0 to 8.5. The glutaraldehyde and the alcohol ethoxylate non-ionic surfactant are chemically bound together, suitably by complexing. These stable solutions can be stored for a period of at least six months without the glutaraldehyde polymerizing or the pH dropping below 5.0.

Abstract: This invention provides stable aqueous glutaraldehyde solution comprising 0.005% to 45% m/v solution of glutaraldehyde, an alcohol exthoxylate non-ionic surfactant, sodium acetate trihydrate and sufficient of a pH modifier to bring the pH of the solution to 6.0 to 8.5. In particular, the invention relates to stable concentrate solutions comprising 10% to 45% m/v glutaraldehyde. These stable solutions can be stored for a period of at least six months without the glutaraldehyde polymerising or the pH dropping below 5.0.

Abstract: A stable, aqueous, glutaraldehyde solution comprising:an aqueous solution of glutaraldehyde;a non-ionic detergent;sodium acetate; andsufficient of a pH modifier to bring the pH of the solution to 6 to 8.5 is provided.The solution does not require an activator prior to use and is not a skin irritant. It is also stable for a period of up to 6 months at temperatures of 25.degree. C. when undiluted. When diluted further with water to differing concentrations, it is suitable for use as a sterilising, cleaning, disinfecting, antiseptic, subcutaneously injectable or preservative end use composition. These diluted compositions are stable for a period of up to 12 months and also require no activation prior to use.